Abstract Number: 2858 • 2018 ACR/ARHP Annual Meeting
Gaps in Patient Safety Performance before Treatment with Biologic Disease-Modifying Antirheumatic Drugs or Tofacitinib in a Large Academic Healthcare System
Background/Purpose: Treatment with biologic disease-modifying antirheumatic drugs (DMARDs) and tofacitinib confer increased risk of life-threatening infections, including reactivation of latent tuberculosis infection (LTBI), hepatitis B…Abstract Number: 2859 • 2018 ACR/ARHP Annual Meeting
Do Preventive Cardiology Consults Versus Usual Care Improve Cardiovascular Risk Factor Assessment and Management in Patients with Rheumatoid Arthritis?
Background/Purpose: Rheumatoid arthritis (RA) patients have around 50% increased risk of cardiovascular disease (CVD). Both traditional and RA-specific cardiovascular (CV) risk factors contribute to the…Abstract Number: 2860 • 2018 ACR/ARHP Annual Meeting
Disease Activity and Its Measurement in Patients with RA across the U.S.: Data from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Background/Purpose: Although national quality measures promote the measurement of disease activity (DA) in RA, the burden of DA in a population-based sample of RA patients…Abstract Number: 2861 • 2018 ACR/ARHP Annual Meeting
Clinical Laboratory Telephone Communication Outreach to Rheumatology Patients Improves Guideline-Concordant Timeliness of Monitoring of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
Background/Purpose: The American College of Rheumatology has published guidelines for laboratory monitoring of conventional DMARDs (cDMARDs). At Kaiser Permanente Colorado (KPCO), although most patients eventually…Abstract Number: 2862 • 2018 ACR/ARHP Annual Meeting
Magnitude of Response to TNF Inhibitors in Children with Spondyloarthritis and Sacroiliitis
Background/Purpose: We aimed to quantify the magnitude of biologic effect on sacroiliitis in juvenile SpA by comparing the change in the Spondyloarthritis Research Consortium of…Abstract Number: 2863 • 2018 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant FMF (crFMF), Hids/Mkd and TRAPS: Results from the Pivotal Phase 3 Cluster Trial
Background/Purpose: Canakinumab (CAN), a selective, human anti-interleukin (IL)-1β has demonstrated efficacy and safety in patients (pts) with colchicine-resistant familial Mediterranean fever (crFMF), hyper-IgD syndrome (HIDS)/mevalonate…Abstract Number: 2864 • 2018 ACR/ARHP Annual Meeting
Identification of Optimal Subcutaneous Doses of Tocilizumab in Children with Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Efficacy and safety of intravenous (IV) tocilizumab (TCZ) were shown in patients (pts) with systemic JIA (sJIA) in the phase 3 TENDER study.1 This…Abstract Number: 2865 • 2018 ACR/ARHP Annual Meeting
Canakinumab, on a Reduced Dose or a Prolonged Dose Interval without Concomitant Corticosteroids and Methotrexate, Maintains Efficacy in Systemic Juvenile Idiopathic Arthritis Patients in Clinical Remission
Background/Purpose: Treatment with canakinumab (CAN), a selective, human anti-IL-1β monoclonal antibody, has shown sustained therapeutic effect along with corticosteroid dose reduction/discontinuation in patients with systemic…Abstract Number: 2866 • 2018 ACR/ARHP Annual Meeting
Biologic Refractory Disease in a Cohort Study of Children and Young People with Juvenile Idiopathic Arthritis from the United Kingdom
Background/Purpose: Biologics are a main treatment option for children and young people with juvenile idiopathic arthritis (JIA) who do not respond or are intolerant to…Abstract Number: 2867 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus
Background/Purpose: Belimumab (BEL) is approved in adults with active systemic lupus erythematosus (SLE). There are no approved biologic therapies for pediatric patients with childhood-onset SLE…Abstract Number: 2868 • 2018 ACR/ARHP Annual Meeting
Tender Joint Count May Not Reflect Inflammatory Activity in Established Rheumatoid Arthritis Patients; Results from a Longitudinal Study of Tocilizumab
Background/Purpose: Tender joints may be caused by non-inflammatory pathologies but are still included in composite scores like CDAI. The present objective was to explore the…Abstract Number: 2869 • 2018 ACR/ARHP Annual Meeting
Incorporation of Patient Reported Outcomes Data in the Care of US Veterans with Rheumatoid Arthritis: A Randomized, Controlled Trial
Background/Purpose: Quantitative disease activity measures are required to implement a treat-to-target algorithm for the treatment of rheumatoid arthritis (RA). Available measures based on patient-derived data…Abstract Number: 2870 • 2018 ACR/ARHP Annual Meeting
Thresholds for Disease Activity Measures DAS28, CDAI, and RAPID3 Do Not Align with Clinical Practice Patterns of Rheumatoid Arthritis (RA) Disease Management Decisions
Background/Purpose: Treatment guidelines recommend using disease activity measures (DAMs) to guide RA therapy, but DAM use in real-world treatment decisions is not defined. We…Abstract Number: 2871 • 2018 ACR/ARHP Annual Meeting
Comprehensive Provider Judgement Is a Significant Determinant of Major Therapeutic Change in Patients with Moderate to Severe Rheumatoid Arthritis
Background/Purpose: We have previously reported an evaluation of 941 US Veterans in the Veterans Affairs (VA) Rheumatoid Arthritis (RA) (VARA) registry that 559 (59%)…Abstract Number: 2872 • 2018 ACR/ARHP Annual Meeting
Variation in Predictors of Patient and Physician Defined Flares in Rheumatoid Arthritis
Background/Purpose: The identification of risk factors associated with flares in RA is challenging because of the use of different composite disease activity scores and a…
ACR Meeting Abstracts